Senti Biosciences Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 25, 2024, details a material definitive agreement entered into by Senti Biosciences, Inc. (SNTI) on December 2, 2024. The filing announces a private placement offering of Series A Convertible Preferred Stock and accompanying warrants to raise capital for working capital, general corporate purposes, and the advancement of the SENTI-202 program. The report also discloses changes to the Board of Directors.
Key Financial Metrics and Transaction Details
The filing does not provide historical revenue, profit, or cash flow metrics as it is a current report regarding a specific transaction. Key financial terms of the offering include:
- Total Offering Size: Up to $47.6 million aggregate offering price.
- Initial Closing: Estimated gross proceeds of approximately $37.6 million for 16,713 shares of Series A Preferred Stock and warrants to purchase 25,069,500 shares of Common Stock.
- Additional Closing Option: Up to $9.9 million for an additional 4,444 shares of Series A Preferred Stock and warrants to purchase 6,666,000 shares of Common Stock.
- Preferred Stock Price: $2,250.00 per share.
- Conversion Price: $2.25 per share of Common Stock (1,000 shares per Preferred share).
- Warrant Exercise Price: $2.30 per share.
- Dividend Rate: 18% per annum, compounded annually, accruing on the Original Per Share Price.
- Liquidation Preference: 3x the Original Per Share Price plus accrued dividends.
- Placement Agent Fees: The greater of $1.5 million or 6% of gross proceeds.
Material Changes and Governance
The filing reports significant changes to the Company's capital structure and Board of Directors:
- Resignation: Omid Farokhzad, M.D., resigned from the Board and Audit Committee effective November 25, 2024. The resignation was not due to any dispute with the Company.
- New Appointments:
- Fran Schulz: Appointed to fill the vacancy left by Dr. Farokhzad, effective upon the initial closing of the Offering. She will serve on the Audit Committee.
- Donald Tang: Appointed as a director designated by Celadon Partners, effective upon the closing of the Offering. The Board size increased from five to six members.
- Brenda Cooperstone: Appointed to the Audit Committee in addition to her existing role on the Compensation Committee.
- Investor Relations: Investors include entities affiliated with New Enterprise Associates (NEA) and Bayer Healthcare, LLC, both of which hold more than 5% of the Company's outstanding capital stock.
Outlook, Risks, and Contingencies
Use of Proceeds: Net proceeds are intended for working capital, general corporate purposes, research and development, and advancing the SENTI-202 program.
Conditions Precedent: Conversion of the Series A Preferred Stock and exercise of Warrants are subject to Stockholder Approval. The Company must file a resale registration statement (Form S-3 or S-1) within 120 days of closing.
Risks and Contingencies:
- Redemption Obligation: Holders may require the Company to redeem shares at the Liquidation Preference (3x price plus dividends) starting 210 days after issuance. The Company must apply all assets to such redemption if triggered.
- Liquidated Damages: The Company agreed to pay penalties up to 5% of the aggregate subscription amount if it fails to meet registration statement deadlines.
- Forward-Looking Statements: The filing includes standard disclaimers regarding uncertainties in the timing of the Offering and the use of proceeds.
Investor Verification Checklist
- Verify the status of the Stockholder Approval required for the conversion of Series A Preferred Stock and exercise of Warrants.
- Confirm the final closing date and total gross proceeds raised, including whether the additional $9.9 million option was exercised.
- Review the Company's cash position to assess its ability to meet the potential 3x liquidation preference redemption obligation if triggered by investors.
- Monitor the filing of the resale registration statement (Form S-3 or S-1) to ensure compliance with the 120-day deadline and avoid liquidated damages.
- Check for any updates regarding the progress of the SENTI-202 program, which is a primary use of the raised capital.